Bartlett & CO. Wealth Management LLC Raises Stock Holdings in AstraZeneca PLC $AZN

Bartlett & CO. Wealth Management LLC lifted its stake in AstraZeneca PLC (NASDAQ:AZN) by 46.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,267 shares of the company’s stock after buying an additional 716 shares during the quarter. Bartlett & CO. Wealth Management LLC’s holdings in AstraZeneca were worth $158,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Larson Financial Group LLC lifted its holdings in AstraZeneca by 297.9% during the first quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock valued at $28,000 after purchasing an additional 289 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in shares of AstraZeneca during the 1st quarter valued at $29,000. Costello Asset Management INC purchased a new position in shares of AstraZeneca during the 1st quarter valued at $29,000. Highline Wealth Partners LLC boosted its holdings in AstraZeneca by 447.4% in the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company’s stock worth $31,000 after buying an additional 340 shares during the period. Finally, Maseco LLP purchased a new stake in AstraZeneca in the 2nd quarter worth $34,000. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

AZN opened at $83.65 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. The stock has a market capitalization of $259.43 billion, a price-to-earnings ratio of 31.45, a PEG ratio of 1.55 and a beta of 0.36. The company has a fifty day moving average of $77.79 and a 200 day moving average of $73.04. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $84.61.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The business had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. During the same quarter in the prior year, the firm earned $1.24 EPS. The business’s revenue was up 16.1% on a year-over-year basis. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were paid a $0.505 dividend. The ex-dividend date of this dividend was Friday, August 8th. This represents a yield of 200.0%. AstraZeneca’s payout ratio is presently 37.97%.

Analyst Ratings Changes

Separately, Berenberg Bank set a $97.00 price target on AstraZeneca in a report on Wednesday, July 9th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.